Previous studies have established GPX4 and SLC7A11 as downstream targets of Nrf2, where Nrf2 activation leads to GPX4 overexpression in AML, contributing to chemoresistance and ferroptosis evasion (Liu et al., 2023). The gene discussed is GPX4; the disease is acute myeloid leukemia.